Balanced news tone
News Sentiment
OCS sentiment intelligence
Oculis Holding AG Ordinary shares news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
News tone and price action are not far from neutral.
78/100 classification confidence.
directly relevant articles
high-authority source matches
-3.5% over one week, +22.9% over four weeks, trend inactive, and near fair-value range.
Oculis Holding AG (OCS) Investigation: Bronstein, Gewirtz & Gross
Market Reaction
Balanced read
News tone and price action are not far from neutral.
Sentiment Mix
Positive, neutral, negative
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
News Tape
Relevant headlines
Nan Fung Group Sells $4.3 Million in Oculis Shares As Lead Drug Stumbles
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 08 Jun 2026 11:16
- Source
- Motley Fool
Eye drug maker Oculis to outline $7B+ optic neuritis market plan
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 08 Jun 2026 07:00
- Source
- Stock Titan
Oculis Holding AG (OCS) Securities Fraud Investigation - Levi & Korsinsky
- Tone
- Negative 34/100
- Event
- Regulatory and legal
- Published
- 08 Jun 2026 07:00
- Source
- Morningstar
Lost Money on Oculis Holding AG (OCS)? Contact Levi & Korsinsky About Investigation
- Tone
- Negative 34/100
- Event
- Regulatory and legal
- Published
- 08 Jun 2026 07:00
- Source
- TMX Newsfile
Oculis Holding (OCS) Is Down 60.1% After OCS-01 Trial Failure And Pipeline Pivot – Has The Bull Case Changed?
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 05 Jun 2026 07:00
- Source
- simplywall.st
OCS Stock Price and Chart — NASDAQ:OCS
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 04 Jun 2026 07:00
- Source
- TradingView
Levi & Korsinsky Announces Investigation of Securities Claims Against Oculis Holding AG (OCS)
- Tone
- Negative 34/100
- Event
- Regulatory and legal
- Published
- 04 Jun 2026 07:00
- Source
- GlobeNewswire
OCS Investor Alert: Levi & Korsinsky Investigates Oculis Holding AG (OCS) for Potential Securities Fraud
- Tone
- Neutral 50/100
- Event
- Regulatory and legal
- Published
- 03 Jun 2026 07:00
- Source
- Business Wire
Oculis Resets After OCS-01 Setback And Refocuses On Late-Stage Pipeline
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 02 Jun 2026 07:00
- Source
- simplywall.st
How Fair Value analysis helped investors avoid a 42% loss in Oculis By Investing.com
- Tone
- Negative 34/100
- Event
- Market update
- Published
- 02 Jun 2026 07:00
- Source
- Investing.com
Oculis Holding AG Investigation Initiated: Levi & Korsinsky Investigates the Officers and Directors of Oculis Holding AG (OCS)
- Tone
- Negative 34/100
- Event
- Regulatory and legal
- Published
- 01 Jun 2026 07:00
- Source
- PR Newswire
Oculis Shelves FDA Filing After Phase 3 DME Trials Miss Key Vision Goals
- Tone
- Negative 42/100
- Event
- Market update
- Published
- 31 May 2026 21:03
- Source
- MarketBeat
Oculis Holding AG Phase 3 Trial of Potential Eye Drops for Diabetic Patients Fails to Primary Endpoint
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 29 May 2026 19:46
- Source
- MT Newswires
Oculis Announces Phase 3 Trial Results for OCS-01 Eye Drops in Diabetic Macular Edema, Shifts Focus to Other Development Programs
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 29 May 2026 07:00
- Source
- Quiver Quantitative
There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings
- Tone
- Negative 34/100
- Event
- Earnings
- Published
- 15 May 2026 07:00
- Source
- simplywall.st
Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 14 May 2026 07:00
- Source
- Market source
Weighing Oculis Holding (NasdaqGM:OCS) Rich P/B Against DCF Upside After Strong Multi Year Share Gains
- Tone
- Positive 95/100
- Event
- Market update
- Published
- 11 May 2026 07:00
- Source
- Market source
Oculis Holding AG (OCS) Reports Q1 Loss, Lags Revenue Estimates
- Tone
- Negative 34/100
- Event
- Earnings
- Published
- 11 May 2026 07:00
- Source
- Market source
Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results
- Tone
- Positive 66/100
- Event
- Earnings
- Published
- 11 May 2026 07:00
- Source
- simplywall.st
Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 11 May 2026 07:00
- Source
- Market source
Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 25 Apr 2026 07:00
- Source
- Market source
Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 21 Apr 2026 07:00
- Source
- Market source
A Look Back at Biotechnology Stocks’ Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 29 Mar 2026 07:00
- Source
- TradingView